FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a coformulated drug exhibiting antituberculous action and representing a solid dosage form which contains as an active principle a formulation of rifampicin, isoniazid, pyrazinamide, and a zinc-containing compound, and pharmaceutically acceptable excipients. The zinc-containing compound is zinc salt, preferentially zinc sulphate.
EFFECT: pharmaceutical composition under the invention is characterised by high efficacy and provides synergetic antimycobacterial activity when using the formulation of rifampicin, isoniasid, pyrazinamide and zinc sulphate as an antituberculous drug as compared with a formulation of standard antituberculous drugs.
9 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED ANTITUBERCULOUS COMPOSITION | 2009 |
|
RU2413517C1 |
| COMBINED ANTITUBERCULOUS COMPOSITION | 2010 |
|
RU2468802C2 |
| PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION | 2011 |
|
RU2478389C2 |
| METHOD OF TREATING TUBERCULOSIS WITH MULTIPLE DRUG RESISTANCE | 2013 |
|
RU2554753C2 |
| ANTI-TUBERCULOSIS MEDICATION BASED ON 4-THIOUREIDOIMINOMETHYLPYRIDINIUM PERCHLORATE, METHOD OF ITS OBTAINING AND METHOD OF TREATMENT | 2010 |
|
RU2423977C1 |
| SYNERGIC ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSERINE AND ZINC CONTAINING CONNECTION | 2016 |
|
RU2620857C1 |
| COMBINED ANTITUBERCULOUS PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2417087C2 |
| STRAIN MYCOBACTERIUM TUBERCULOSIS 326/18/47 B-9673 FOR EVALUATION OF THE EFFECTIVENESS OF ANTI-TB DRUGS AND DISINFECTANTS | 2022 |
|
RU2785409C1 |
| COMBINED ANTI-TUBERCULOSIS PREPARATION | 2007 |
|
RU2354378C1 |
| PULMONARY TUBERCULOSIS TREATMENT METHOD | 2002 |
|
RU2195313C1 |
